Apixaban Steps Up to the Plate: The Use of Apixaban for Treatment of Venous Thromboemboli in Patients with Cancer

The incidence of venous thromboemboli (VTE) development in patients with cancer has been reported as much as four to seven-fold higher than that for non-cancer patients. Anticoagulation management remains challenging for these patients, due to the higher risk of recurrent VTE (despite anticoagulant therapy) and bleeding complications, compared to patients without cancer. This application-based continuing pharmacy education activity will provide a 'journal club format' discussion for pharmacists and student pharmacists to analyze the long-awaited results of the Caravaggio Trial. Join us for a dynamic discussion reviewing the outcomes and implications of this trial, in light of the current data supporting the use of warfarin, low molecular weight heparins, and direct oral anticoagulants for the treatment of venous thromboemboli in patients with cancer.